Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. is not a good value stock. Pliant Therapeutics, Inc. is not a good growth stock. Pliant Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Pliant Therapeutics, Inc..

News

Pliant Therapeutics: Good Data, But Will Need Watching

SeekingAlpha Pliant Therapeutics: Good Data, But Will Need Watching...\n more…

Leerink Partnrs Weighs in on Pliant Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:PLRX)

Ticker Report Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Pliant Therapeutics in a research note issued to...\n more…

Pliant Therapeutics presents data from its Bexotegrast program

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

Globe Newswire SOUTH SAN FRANCISCO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel...\n more…

Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Leerink Partnrs

Zolmax Leerink Partnrs upgraded shares of Pliant Therapeutics (NASDAQ:PLRX - Free Report) to a strong-buy rating in a research note released on Monday, Zacks.com reports. Leerink Partnrs also issued...\n more…

Pliant Therapeutics (NASDAQ:PLRX) Upgraded by Leerink Partnrs to "Strong-Buy"

Ticker Report Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) was upgraded by equities researchers at Leerink Partnrs to a "strong-buy" rating in a note issued to investors on Monday, Zacks.com reports...\n more…